MXPA05008838A - Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. - Google Patents

Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.

Info

Publication number
MXPA05008838A
MXPA05008838A MXPA05008838A MXPA05008838A MXPA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A
Authority
MX
Mexico
Prior art keywords
rapid absorption
selective
agonist formulations
incorporated
agonist
Prior art date
Application number
MXPA05008838A
Other languages
English (en)
Inventor
Paul Maes
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of MXPA05008838A publication Critical patent/MXPA05008838A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona una composicion farmaceutica de absorcion acelerada que comprende una cantidad efectiva de al menos un agonista selectivo de la 5-HT, al menos un adyuvante de la esferonizacion y al menos un mejorador de la solubilidad. La composicion de la invencion se incorpora en microparticulas, las cuales pueden tener sabor enmascarado y posteriormente se incorporan en una variedad de formas de dosificacion para la administracion a un paciente que sufre de migrana.
MXPA05008838A 2003-02-19 2004-02-18 Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. MXPA05008838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774103P 2003-02-19 2003-02-19
PCT/US2004/004572 WO2004073632A2 (en) 2003-02-19 2004-02-18 Rapid absorption selective 5-ht agonist formulations

Publications (1)

Publication Number Publication Date
MXPA05008838A true MXPA05008838A (es) 2006-02-17

Family

ID=32908492

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008838A MXPA05008838A (es) 2003-02-19 2004-02-18 Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.

Country Status (8)

Country Link
US (1) US20040162333A1 (es)
EP (1) EP1594470A4 (es)
JP (1) JP2006523620A (es)
AU (1) AU2004212976A1 (es)
CA (1) CA2514875A1 (es)
MX (1) MXPA05008838A (es)
NO (1) NO20054015L (es)
WO (1) WO2004073632A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409127A (pt) * 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
EP1793808A1 (en) * 2004-09-29 2007-06-13 Aurobindo Pharma Limited Solid unit dosage forms of 5-ht1 agonist
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
AU2006338839A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TW200835527A (en) * 2006-12-26 2008-09-01 Shionogi & Co Orally disintegrating tablet and bitter taste-masked formulation comprising risperidone
US8778392B2 (en) 2007-03-13 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
DK2214677T3 (da) 2007-11-13 2017-11-20 Meritage Pharma Inc Sammensætninger til behandling af inflammation i mavetarmkanalen
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
ES2655719T3 (es) * 2009-07-10 2018-02-21 Merck Patent Gmbh Sustancia auxiliar con bajo contenido de agua para formación de comprimidos y procedimiento para su fabricación
US8551529B2 (en) * 2009-07-10 2013-10-08 Merck Patent Gmbh Composition for the production of tablets, and method for the production of said composition
US8906949B2 (en) 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
US8901159B2 (en) 2010-07-01 2014-12-02 Allergan, Inc. Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AR089857A1 (es) * 2012-02-02 2014-09-24 Glaxosmithkline Llc Comprimido antiacido para refrescar el aliento
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CA2991108A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
MX9603480A (es) * 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
TR199902140T2 (en) * 1997-03-03 2000-04-21 F. Hoffmann-La Roche Ag S�bstit�e edilmi� 2,4-diaminopirimidinler.
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
JP2004525854A (ja) * 1999-06-02 2004-08-26 ヘキサル・アクチェンゲゼルシャフト 水中に不溶性及び／又は難溶性である活性物質の鼻腔内投与用薬剤組成物
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
JP2002037745A (ja) * 2000-07-25 2002-02-06 ▲高▼田 ▲寛▼治 水溶性の難・低吸収性薬物のバイオアベイラビリティ改善技術
CA2432642A1 (en) * 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque

Also Published As

Publication number Publication date
AU2004212976A1 (en) 2004-09-02
EP1594470A4 (en) 2007-10-17
NO20054015D0 (no) 2005-08-30
NO20054015L (no) 2005-09-16
EP1594470A2 (en) 2005-11-16
WO2004073632A3 (en) 2004-11-18
CA2514875A1 (en) 2004-09-02
JP2006523620A (ja) 2006-10-19
US20040162333A1 (en) 2004-08-19
WO2004073632A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1663194T3 (da) Anvendelse af SAHA til behandling af mesotheliom
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
AU2003301190A1 (en) Administration of capsaicinoids
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
WO2005018565A3 (en) Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
NO20043367L (no) Oralt farmasoytisk preparat
MX2007005238A (es) Una composicion veterinaria transmucosal que comprende detomidina.
HK1080390A1 (en) Pharmaceutical composition for thrombin peptide derivatives
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
GEP201606538B (en) Preoperative treatment of post operative pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal